marketcaparena
Search

    UTHR

    UNITED THERAPEUTICS Corp

    Company overview

    Market capitalization
    $20.83B
    Employees
    1,400
    Latest publication
    2026-09-29
    About UNITED THERAPEUTICS Corp

    United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue783,300,000USD781,500,000USD790,200,000USD799,500,000USD798,600,000USD794,400,000USD735,900,000USD748,900,000USD
    Cost Of Revenue99,500,000USD133,400,000USD103,400,000USD100,900,000USD87,600,000USD92,500,000USD75,900,000USD83,100,000USD
    Gross Profit683,800,000USD648,100,000USD686,800,000USD698,600,000USD711,000,000USD701,900,000USD660,000,000USD665,800,000USD
    Research Development146,300,000USD138,200,000USD139,500,000USD127,500,000USD134,000,000USD149,000,000USD133,800,000USD103,500,000USD
    Selling General Administrative206,700,000USD155,400,000USD157,100,000USD153,500,000USD159,800,000USD143,500,000USD135,500,000USD198,500,000USD
    Total Operating Expenses353,000,000USD322,300,000USD329,300,000USD309,300,000USD346,500,000USD319,100,000USD302,300,000USD322,700,000USD
    Operating Income330,800,000USD325,800,000USD357,500,000USD389,300,000USD364,500,000USD382,800,000USD357,700,000USD343,100,000USD
    Total Other Income Expense Net41,900,000USD-7,500,000USD86,500,000USD48,700,000USD43,900,000USD40,700,000USD38,800,000USD45,500,000USD
    Interest Income31,500,000USD41,800,000USD43,200,000USD46,400,000USD51,300,000USD51,100,000USD49,300,000USD49,800,000USD
    Interest Expense2,900,000USD3,000,000USD3,100,000USD3,000,000USD7,300,000USD6,100,000USD7,900,000USD10,100,000USD
    Income Before Tax372,700,000USD318,300,000USD444,000,000USD438,000,000USD408,400,000USD423,500,000USD396,500,000USD388,600,000USD
    Income Tax Expense39,700,000USD43,400,000USD79,700,000USD99,300,000USD98,900,000USD101,300,000USD95,200,000USD79,500,000USD
    Net Income333,000,000USD274,900,000USD364,300,000USD338,700,000USD309,500,000USD322,200,000USD301,300,000USD309,100,000USD
    Selling And Marketing Expenses—28,700,000USD32,700,000USD28,300,000USD31,000,000USD26,600,000USD27,000,000USD20,700,000USD
    Net Interest Income—38,800,000USD40,100,000USD43,400,000USD44,000,000USD45,000,000USD41,400,000USD39,700,000USD
    Tax Provision—43,400,000USD79,700,000USD99,300,000USD98,900,000USD101,300,000USD95,200,000USD79,500,000USD
    Net Income From Continuing Ops—274,900,000USD364,300,000USD338,700,000USD309,500,000USD322,200,000USD301,300,000USD309,100,000USD
    Ebit—321,300,000USD447,100,000USD441,000,000USD415,700,000USD417,400,000USD404,400,000USD398,700,000USD
    Ebitda—343,900,000USD469,900,000USD462,900,000USD436,800,000USD437,200,000USD424,100,000USD417,800,000USD
    Depreciation And Amortization—22,600,000USD22,800,000USD21,900,000USD21,100,000USD19,800,000USD19,700,000USD19,100,000USD
    Reconciled Depreciation—22,600,000USD22,800,000USD21,900,000USD21,100,000USD19,800,000USD19,700,000USD19,100,000USD
    Unclassified Operating Expenses————21,700,000USD—6,000,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Total Revenue3,182,700,000USD2,877,400,000USD2,327,500,000USD1,936,300,000USD1,685,500,000USD1,483,300,000USD1,627,800,000USD1,725,300,000USD
    Cost Of Revenue384,400,000USD309,700,000USD257,500,000USD146,700,000USD122,500,000USD108,100,000USD198,700,000USD105,700,000USD
    Gross Profit2,798,300,000USD2,567,700,000USD2,070,000,000USD1,789,600,000USD1,563,000,000USD1,375,200,000USD1,429,100,000USD1,619,600,000USD
    Research Development550,000,000USD481,000,000USD408,000,000USD322,900,000USD540,100,000USD357,700,000USD357,900,000USD264,600,000USD
    Selling General Administrative612,500,000USD542,300,000USD395,300,000USD416,200,000USD402,600,000USD369,000,000USD206,700,000USD265,800,000USD
    Selling And Marketing Expenses118,600,000USD96,300,000USD81,800,000USD70,800,000USD64,400,000USD54,900,000USD59,100,000USD64,300,000USD
    Total Operating Expenses1,281,100,000USD1,190,700,000USD885,100,000USD809,900,000USD1,007,100,000USD781,600,000USD623,700,000USD594,700,000USD
    Operating Income1,517,200,000USD1,377,000,000USD1,184,900,000USD979,700,000USD555,900,000USD593,600,000USD805,400,000USD814,900,000USD
    Interest Income192,000,000USD199,100,000USD162,700,000USD45,200,000USD16,700,000USD28,600,000USD28,600,000USD9,000,000USD
    Interest Expense19,500,000USD42,900,000USD59,300,000USD32,400,000USD18,600,000USD23,500,000USD13,900,000USD9,000,000USD
    Net Interest Income172,500,000USD156,200,000USD103,400,000USD12,800,000USD-1,900,000USD5,100,000USD14,700,000USD-9,000,000USD
    Income Before Tax1,713,900,000USD1,539,000,000USD1,274,300,000USD950,600,000USD593,900,000USD638,900,000USD758,900,000USD769,500,000USD
    Income Tax Expense379,200,000USD343,900,000USD289,500,000USD223,300,000USD118,100,000USD124,100,000USD169,700,000USD351,600,000USD
    Tax Provision379,200,000USD343,900,000USD289,500,000USD223,300,000USD118,100,000USD124,100,000USD169,700,000USD351,600,000USD
    Net Income1,334,700,000USD1,195,100,000USD984,800,000USD727,300,000USD475,800,000USD514,800,000USD589,200,000USD417,900,000USD
    Net Income From Continuing Ops1,334,700,000USD1,195,100,000USD984,800,000USD727,300,000USD475,800,000USD514,800,000USD589,200,000USD417,900,000USD
    Ebit1,733,400,000USD1,581,900,000USD1,333,600,000USD989,000,000USD686,900,000USD596,400,000USD802,500,000USD1,022,400,000USD
    Ebitda1,819,000,000USD1,654,400,000USD1,386,800,000USD1,040,300,000USD736,800,000USD646,300,000USD838,400,000USD1,053,400,000USD
    Depreciation And Amortization85,600,000USD72,500,000USD53,200,000USD51,300,000USD49,900,000USD49,900,000USD35,900,000USD31,000,000USD
    Reconciled Depreciation85,600,000USD72,500,000USD53,200,000USD51,300,000USD49,900,000USD49,900,000USD35,900,000USD31,000,000USD
    Total Other Income Expense Net196,700,000USD162,000,000USD89,400,000USD-29,100,000USD38,000,000USD45,300,000USD-46,500,000USD-45,400,000USD
    Unclassified Operating Expenses—71,100,000USD——————
    Non Operating Income Net Other———3,300,000USD56,600,000USD68,800,000USD-32,600,000USD-36,400,000USD
    Net Income Applicable To Common Shares———727,300,000USD475,800,000USD514,800,000USD589,200,000USD417,900,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets7,220,100,000USD6,714,200,000USD7,880,000,000USD7,351,100,000USD7,908,000,000USD7,743,900,000USD7,364,000,000USD7,123,100,000USD
    Cash And Equivalents1,803,200,000USD———————
    Cash And Short Term Investments2,662,300,000USD2,153,700,000USD1,557,100,000USD2,767,600,000USD3,048,700,000USD3,321,300,000USD3,267,000,000USD3,326,500,000USD
    Short Term Investments859,100,000USD1,079,500,000USD1,363,200,000USD1,631,000,000USD1,455,600,000USD1,421,400,000USD1,569,800,000USD1,772,600,000USD
    Long Term Investments1,141,100,000USD1,317,400,000USD1,776,700,000USD1,567,300,000USD1,917,700,000USD1,710,700,000USD1,475,300,000USD1,279,400,000USD
    Total Current Assets3,483,700,000USD2,872,000,000USD3,702,500,000USD3,494,000,000USD3,826,900,000USD3,939,800,000USD3,873,900,000USD4,000,400,000USD
    Other Current Assets317,300,000USD228,000,000USD1,612,100,000USD252,200,000USD229,700,000USD131,100,000USD169,700,000USD185,400,000USD
    Other Non Current Assets239,500,000USD———————
    Total Liabilities819,800,000USD———————
    Total Current Liabilities607,800,000USD599,100,000USD560,600,000USD546,300,000USD527,100,000USD721,500,000USD738,100,000USD873,400,000USD
    Other Current Liabilities110,000,000USD———————
    Other Non Current Liabilities212,000,000USD———————
    Total Stockholder Equity6,400,300,000USD5,901,100,000USD7,096,200,000USD6,590,200,000USD7,173,600,000USD6,807,200,000USD6,444,000,000USD6,100,900,000USD
    Total Equity Including Noncontrolling Interest6,400,300,000USD———————
    Net Receivables310,300,000USD312,000,000USD350,200,000USD297,700,000USD379,300,000USD322,000,000USD279,300,000USD341,800,000USD
    Inventory193,800,000USD178,300,000USD183,100,000USD176,500,000USD169,200,000USD165,400,000USD157,900,000USD146,700,000USD
    Property Plant Equipment Net1,930,100,000USD1,840,700,000USD1,729,700,000USD1,555,600,000USD1,362,400,000USD1,302,700,000USD1,222,400,000USD1,156,700,000USD
    Accounts Payable497,800,000USD498,300,000USD7,100,000USD468,000,000USD432,000,000USD367,000,000USD6,000,000USD363,900,000USD
    Common Stock800,000USD800,000USD800,000USD800,000USD800,000USD800,000USD800,000USD700,000USD
    Retained Earnings9,164,800,000USD8,831,800,000USD8,556,900,000USD8,192,600,000USD7,853,900,000USD7,544,400,000USD7,222,200,000USD6,920,900,000USD
    Accumulated Other Comprehensive Income-16,200,000USD-10,200,000USD900,000USD100,000USD—-1,200,000USD-3,400,000USD7,400,000USD
    Intangible Assets—115,500,000USD116,500,000USD116,700,000USD111,500,000USD111,700,000USD79,600,000USD112,100,000USD
    Total Liab—813,100,000USD783,800,000USD760,900,000USD734,400,000USD936,700,000USD920,000,000USD1,022,200,000USD
    Other Current Liab—100,800,000USD553,500,000USD78,300,000USD95,100,000USD154,500,000USD432,100,000USD109,500,000USD
    Capital Stock—800,000USD800,000USD800,000USD800,000USD800,000USD800,000USD700,000USD
    Cash—1,074,200,000USD1,557,100,000USD1,136,600,000USD1,593,100,000USD1,899,900,000USD1,697,200,000USD1,553,900,000USD
    Net Debt—-1,074,200,000USD-1,557,100,000USD-1,136,600,000USD-1,593,100,000USD-1,699,900,000USD-1,397,200,000USD-1,153,900,000USD
    Property Plant Equipment Gross—2,430,000,000USD2,297,500,000USD2,104,200,000USD1,893,700,000USD1,813,400,000USD1,713,600,000USD1,632,300,000USD
    Common Stock Shares Outstanding—47,200,000shares47,900,000shares47,300,000shares48,300,000shares48,600,000shares48,700,000shares48,400,000shares
    Non Current Assets Total—3,842,200,000USD4,177,500,000USD3,857,100,000USD4,081,100,000USD3,804,100,000USD3,490,100,000USD3,122,700,000USD
    Non Current Liabilities Total—214,000,000USD223,200,000USD214,600,000USD207,299,999USD215,200,000USD181,900,000USD148,800,000USD
    Non Current Liabilities Other—214,000,000USD223,200,000USD214,600,000USD207,300,000USD215,200,000USD181,900,000USD148,800,000USD
    Non Currrent Assets Other—141,600,000USD196,900,000USD173,600,000USD233,300,000USD222,400,000USD222,100,000USD183,600,000USD
    Net Working Capital—2,272,900,000USD3,141,900,000USD2,947,700,000USD3,299,800,000USD3,218,300,000USD3,135,800,000USD3,127,000,000USD
    Unclassified Non Current Assets—427,000,000USD325,400,000USD443,900,000USD456,200,000USD456,600,000USD458,400,000USD390,900,000USD
    Unclassified Equity—-2,922,100,000USD-1,463,200,000USD-1,604,100,000USD-681,900,000USD-737,600,000USD-776,400,000USD-828,800,000USD
    Good Will——32,300,000USD———32,300,000USD—
    Unclassified Current Assets——-1,363,200,000USD—————
    Short Term Debt—————200,000,000USD300,000,000USD400,000,000USD
    Short Long Term Debt—————200,000,000USD300,000,000USD400,000,000USD
    Short Long Term Debt Total—————200,000,000USD300,000,000USD400,000,000USD
    Unclassified Current Liabilities—————-200,000,000USD-300,000,000USD-400,000,000USD
    Current Deferred Revenue———————-363,900,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets7,880,000,000USD7,364,000,000USD7,167,000,000USD6,044,500,000USD5,169,100,000USD4,615,000,000USD3,913,400,000USD3,401,000,000USD
    Intangible Assets116,500,000USD79,600,000USD80,500,000USD16,500,000USD16,600,000USD130,100,000USD130,300,000USD139,300,000USD
    Other Current Assets1,612,100,000USD169,700,000USD166,200,000USD219,200,000USD100,400,000USD88,300,000USD-633,700,000USD75,400,000USD
    Total Liab783,800,000USD920,000,000USD1,182,200,000USD1,247,800,000USD1,210,200,000USD1,219,800,000USD1,133,000,000USD612,400,000USD
    Total Stockholder Equity7,096,200,000USD6,444,000,000USD5,984,800,000USD4,796,700,000USD3,958,900,000USD3,395,200,000USD2,780,400,000USD2,788,600,000USD
    Other Current Liab553,500,000USD432,100,000USD398,800,000USD339,100,000USD301,600,000USD319,200,000USD39,600,000USD253,500,000USD
    Common Stock800,000USD800,000USD700,000USD700,000USD700,000USD700,000USD700,000USD700,000USD
    Capital Stock800,000USD800,000USD700,000USD700,000USD700,000USD700,000USD700,000USD19,900,000USD
    Retained Earnings8,556,900,000USD7,222,200,000USD6,027,100,000USD5,042,300,000USD4,315,000,000USD3,839,200,000USD3,325,200,000USD3,434,800,000USD
    Good Will32,300,000USD32,300,000USD33,700,000USD28,000,000USD28,000,000USD28,000,000USD28,000,000USD31,500,000USD
    Cash1,557,100,000USD1,697,200,000USD1,207,700,000USD961,200,000USD894,800,000USD738,700,000USD738,400,000USD669,200,000USD
    Cash And Short Term Investments1,557,100,000USD3,267,000,000USD2,994,100,000USD2,838,700,000USD1,930,700,000USD1,835,000,000USD1,485,900,000USD1,415,900,000USD
    Total Current Assets3,702,500,000USD3,873,900,000USD3,551,000,000USD3,380,300,000USD2,323,600,000USD2,167,200,000USD1,864,500,000USD1,768,000,000USD
    Total Current Liabilities560,600,000USD738,100,000USD804,400,000USD343,200,000USD305,400,000USD323,300,000USD463,000,000USD276,600,000USD
    Net Debt-1,557,100,000USD-1,397,200,000USD-507,700,000USD-161,200,000USD-94,800,000USD61,300,000USD111,600,000USD-419,200,000USD
    Long Term Investments1,776,700,000USD1,475,300,000USD1,909,800,000USD1,316,200,000USD1,649,900,000USD1,149,600,000USD767,500,000USD442,600,000USD
    Short Term Investments1,363,200,000USD1,569,800,000USD1,786,400,000USD1,877,500,000USD1,035,900,000USD1,096,300,000USD747,500,000USD746,700,000USD
    Net Receivables350,200,000USD279,300,000USD278,900,000USD220,400,000USD198,700,000USD157,400,000USD151,400,000USD175,700,000USD
    Inventory183,100,000USD157,900,000USD111,800,000USD102,000,000USD93,800,000USD86,500,000USD93,400,000USD101,000,000USD
    Accounts Payable7,100,000USD6,000,000USD5,600,000USD4,100,000USD3,800,000USD4,100,000USD9,900,000USD23,100,000USD
    Property Plant Equipment Net1,729,700,000USD1,222,400,000USD1,045,400,000USD861,500,000USD780,900,000USD731,600,000USD738,500,000USD699,700,000USD
    Property Plant Equipment Gross2,297,500,000USD1,713,600,000USD1,473,600,000USD1,244,200,000USD1,123,300,000USD731,000,000USD738,500,000USD699,700,000USD
    Accumulated Other Comprehensive Income900,000USD-3,400,000USD-12,800,000USD-55,500,000USD-23,000,000USD-14,200,000USD-14,200,000USD-7,900,000USD
    Common Stock Shares Outstanding47,900,000shares48,500,000shares49,700,000shares48,500,000shares47,300,000shares44,600,000shares43,800,000shares44,000,000shares
    Non Current Assets Total4,177,500,000USD3,490,100,000USD3,616,000,000USD2,664,200,000USD2,845,500,000USD2,447,800,000USD2,048,900,000USD1,633,000,000USD
    Non Current Liabilities Total223,200,000USD181,900,000USD377,800,000USD904,600,000USD904,800,000USD896,500,000USD670,000,000USD316,600,000USD
    Non Current Liabilities Other223,200,000USD181,900,000USD77,800,000USD104,600,000USD104,800,000USD96,500,000USD70,000,000USD66,600,000USD
    Non Currrent Assets Other196,900,000USD222,100,000USD151,800,000USD114,300,000USD108,200,000USD169,900,000USD154,600,000USD224,200,000USD
    Net Working Capital3,141,900,000USD3,135,800,000USD2,746,600,000USD3,037,100,000USD2,018,200,000USD1,843,900,000USD1,401,500,000USD1,491,400,000USD
    Unclassified Current Assets-1,363,200,000USD—————133,800,000USD—
    Unclassified Non Current Assets325,400,000USD458,400,000USD394,800,000USD-85,800,000USD-108,200,000USD-1,320,400,000USD-63,800,000USD-224,200,000USD
    Unclassified Equity-1,463,200,000USD-776,400,000USD—-191,500,000USD-334,500,000USD-431,200,000USD2,047,200,000USD1,920,300,000USD
    Short Term Debt—300,000,000USD400,000,000USD———250,000,000USD—
    Short Long Term Debt—300,000,000USD400,000,000USD———250,000,000USD—
    Short Long Term Debt Total—300,000,000USD700,000,000USD800,000,000USD800,000,000USD800,000,000USD850,000,000USD250,000,000USD
    Unclassified Current Liabilities—-300,000,000USD-727,800,000USD———-250,000,000USD—
    Current Deferred Revenue——327,800,000USD———163,500,000USD—
    Long Term Debt——300,000,000USD800,000,000USD800,000,000USD800,000,000USD600,000,000USD250,000,000USD
    Deferred Long Term Liab———10,500,000USD6,900,000USD9,300,000USD9,300,000USD8,800,000USD
    Other Liab———76,800,000USD104,800,000USD79,400,000USD67,000,000USD85,800,000USD
    Other Assets———413,500,000USD370,100,000USD1,559,000,000USD293,800,000USD319,900,000USD
    Net Tangible Assets———4,752,200,000USD3,914,300,000USD3,237,100,000USD2,622,100,000USD2,637,000,000USD
    Unclassified Non Current Liabilities———-87,300,000USD-111,700,000USD-88,700,000USD-76,300,000USD-94,600,000USD
    Treasury Stock——————-2,579,200,000USD-2,579,200,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation46,800,000USD
    Stock Based Compensation77,300,000USD
    Deferred Income Tax51,600,000USD
    Other Non Cash Items-56,800,000USD
    Change To Account Receivables39,900,000USD
    Change To Inventory-57,800,000USD
    Change To Liabilities-16,700,000USD
    Change In Working Capital-34,600,000USD
    Operating Cash Flow776,900,000USD
    Capital Expenditures-208,800,000USD
    Net Investments1,071,400,000USD
    Unclassified Investing Cash Flow-31,400,000USD
    Investing Cash Flow831,200,000USD
    Net Common Stock Issuance-1,558,800,000USD
    Unclassified Financing Cash Flow196,800,000USD
    Financing Cash Flow-1,362,000,000USD
    Change In Cash246,100,000USD
    End Cash Flow1,803,200,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income274,900,000USD364,300,000USD338,700,000USD309,500,000USD322,200,000USD301,300,000USD309,100,000USD278,100,000USD
    Depreciation22,600,000USD22,800,000USD21,900,000USD21,100,000USD19,800,000USD19,700,000USD19,100,000USD18,700,000USD
    Stock Based Compensation33,900,000USD39,000,000USD39,100,000USD37,800,000USD31,800,000USD27,000,000USD41,700,000USD49,700,000USD
    Other Non Cash Items127,500,000USD-33,600,000USD-100,000USD26,300,000USD9,400,000USD-2,600,000USD-5,700,000USD-5,500,000USD
    Change To Account Receivables38,200,000USD-52,500,000USD81,600,000USD-57,300,000USD-42,700,000USD62,500,000USD-51,100,000USD16,500,000USD
    Change To Inventory-40,100,000USD-16,500,000USD-17,500,000USD-7,400,000USD-11,200,000USD-11,600,000USD-11,300,000USD-14,700,000USD
    Change In Working Capital12,400,000USD-143,900,000USD162,500,000USD-203,000,000USD78,000,000USD-4,200,000USD13,000,000USD-108,800,000USD
    Total Cash From Operating Activities463,300,000USD346,200,000USD562,100,000USD191,700,000USD461,200,000USD341,200,000USD377,200,000USD232,200,000USD
    Capital Expenditures-100,800,000USD-172,900,000USD-210,500,000USD-62,200,000USD-74,900,000USD-86,700,000USD-76,500,000USD-45,100,000USD
    Free Cash Flow362,500,000USD173,300,000USD351,600,000USD129,500,000USD386,300,000USD254,500,000USD300,700,000USD187,100,000USD
    Investments875,200,000USD-34,800,000USD140,900,000USD-299,900,000USD-164,700,000USD-123,200,000USD-114,900,000USD-80,000,000USD
    Total Cashflows From Investing Activities743,700,000USD-227,600,000USD140,900,000USD-299,900,000USD-164,700,000USD-123,200,000USD-114,900,000USD-80,000,000USD
    Net Borrowings0USD0USD0USD-200,000,000USD-100,000,000USD-100,000,000USD-100,000,000USD—
    Total Cash From Financing Activities-1,484,400,000USD98,400,000USD-956,000,000USD-198,600,000USD-93,800,000USD-74,700,000USD-64,100,000USD-48,000,000USD
    Sale Purchase Of Stock-1,500,000,000USD4,400,000USD-1,000,000,000USD-5,200,000USD-15,300,000USD-300,000USD-400,000USD-11,500,000USD
    Change In Cash-482,900,000USD217,000,000USD-253,000,000USD-306,800,000USD202,700,000USD143,300,000USD198,200,000USD104,200,000USD
    Begin Period Cash Flow1,557,100,000USD1,340,100,000USD1,593,100,000USD1,899,900,000USD1,697,200,000USD1,553,900,000USD1,355,700,000USD1,251,500,000USD
    End Period Cash Flow1,074,200,000USD1,557,100,000USD1,340,100,000USD1,593,100,000USD1,899,900,000USD1,697,200,000USD1,553,900,000USD1,355,700,000USD
    Other Cashflows From Investing Activities-5,700,000USD1,270,700,000USD584,800,000USD-600,000USD-9,200,000USD-6,000,000USD-17,800,000USD-900,000USD
    Other Cashflows From Financing Activities-58,300,000USD-33,600,000USD-500,000USD-5,200,000USD-15,300,000USD25,600,000USD36,300,000USD63,500,000USD
    Unclassified Operating Cash Flow-8,000,000USD97,600,000USD——————
    Unclassified Investing Cash Flow-25,000,000USD-1,290,600,000USD-374,300,000USD62,800,000USD84,100,000USD92,700,000USD94,300,000USD46,000,000USD
    Unclassified Financing Cash Flow73,900,000USD127,600,000USD44,500,000USD11,800,000USD36,800,000USD——-100,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income1,334,700,000USD1,195,100,000USD984,800,000USD727,300,000USD475,800,000USD514,800,000USD-104,500,000USD589,200,000USD
    Depreciation85,600,000USD72,500,000USD53,200,000USD51,300,000USD49,900,000USD49,900,000USD45,900,000USD35,900,000USD
    Stock Based Compensation147,700,000USD144,000,000USD39,100,000USD106,800,000USD138,500,000USD163,800,000USD45,400,000USD-26,400,000USD
    Other Non Cash Items2,000,000USD-24,300,000USD-1,300,000USD58,300,000USD108,200,000USD-35,900,000USD-15,100,000USD55,300,000USD
    Change To Account Receivables-70,900,000USD-400,000USD-58,500,000USD-21,700,000USD-41,300,000USD-6,000,000USD24,400,000USD121,400,000USD
    Change To Inventory-52,600,000USD-46,900,000USD-13,600,000USD-13,400,000USD-7,500,000USD10,300,000USD12,900,000USD9,300,000USD
    Change In Working Capital-106,400,000USD-60,200,000USD-97,800,000USD-141,200,000USD-174,200,000USD63,100,000USD-178,300,000USD124,400,000USD
    Total Cash From Operating Activities1,561,200,000USD1,327,100,000USD978,000,000USD802,500,000USD598,200,000USD755,700,000USD-206,600,000USD778,400,000USD
    Capital Expenditures-520,500,000USD-246,500,000USD-230,400,000USD-138,800,000USD-120,800,000USD-59,300,000USD-83,700,000USD-184,400,000USD
    Free Cash Flow1,040,700,000USD1,080,600,000USD747,600,000USD663,700,000USD477,400,000USD696,400,000USD-290,300,000USD594,000,000USD
    Investments40,100,000USD417,200,000USD-951,000,000USD-683,600,000USD-366,100,000USD-681,600,000USD-239,200,000USD-466,100,000USD
    Total Cashflows From Investing Activities-551,300,000USD417,200,000USD-719,600,000USD-811,500,000USD-486,900,000USD-738,500,000USD-335,400,000USD-820,600,000USD
    Net Borrowings-300,000,000USD-400,000,000USD-100,000,000USD-7,500,000USD0USD-51,700,000USD599,300,000USD-13,200,000USD
    Total Cash From Financing Activities-1,150,000,000USD-1,254,800,000USD-11,900,000USD75,400,000USD44,800,000USD-16,900,000USD611,200,000USD6,300,000USD
    Sale Purchase Of Stock-1,000,000,000USD-1,012,200,000USD-13,800,000USD-11,400,000USD-10,800,000USD-3,700,000USD-2,100,000USD19,500,000USD
    Change In Cash-140,100,000USD489,500,000USD246,500,000USD66,400,000USD156,100,000USD300,000USD69,200,000USD-35,900,000USD
    Begin Period Cash Flow1,697,200,000USD1,207,700,000USD961,200,000USD894,800,000USD738,700,000USD738,400,000USD669,200,000USD705,100,000USD
    End Period Cash Flow1,557,100,000USD1,697,200,000USD1,207,700,000USD961,200,000USD894,800,000USD738,700,000USD738,400,000USD669,200,000USD
    Other Cashflows From Investing Activities1,845,700,000USD-28,500,000USD-23,000,000USD3,500,000USD-366,100,000USD2,400,000USD8,000,000USD-46,000,000USD
    Other Cashflows From Financing Activities-33,100,000USD157,400,000USD101,900,000USD86,800,000USD55,600,000USD36,800,000USD13,300,000USD6,300,000USD
    Unclassified Operating Cash Flow97,600,000USD———————
    Unclassified Investing Cash Flow-1,916,600,000USD275,000,000USD484,800,000USD—366,100,000USD—-20,500,000USD-124,100,000USD
    Unclassified Financing Cash Flow183,100,000USD—98,000,000USD101,800,000USD—40,200,000USD14,700,000USD-6,300,000USD
    Dividends Paid——-98,000,000USD-94,300,000USD—-38,500,000USD-14,000,000USD—
    Change To Liabilities———44,500,000USD-12,500,000USD38,600,000USD-16,300,000USD-11,000,000USD
    Cash And Cash Equivalents Changes———66,400,000USD156,100,000USD300,000USD69,200,000USD-35,900,000USD
    Issuance Of Capital Stock———————3,900,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational49,700,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States733,600,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductAdcirca6,700,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNebulized Tyvaso126,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOrenitram125,700,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProduct And Service Other6,800,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRemodulin126,300,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductTyvaso DPI326,600,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductUnituxin65,200,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational37,300,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31GeographyUnited States744,200,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductAdcirca2,900,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductNebulized Tyvaso127,200,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductOrenitram135,600,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductProduct And Service Other5,300,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductRemodulin126,600,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductTyvaso DPI330,300,000USD0001082554-26-000020
    Q1 2026Quarterly · 2026-03-31ProductUnituxin53,600,000USD0001082554-26-000020
    Q4 2025Quarterly · 2025-12-31GeographyInternational37,400,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States752,800,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductAdcirca7,800,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductNebulized Tyvaso125,700,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOrenitram121,200,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductProduct And Service Other6,600,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductRemodulin128,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductTyvaso DPI338,600,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductUnituxin62,300,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational145,700,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31GeographyUnited States3,037,000,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductAdcirca30,000,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductNebulized Tyvaso585,700,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductOrenitram496,900,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductProduct And Service Other24,000,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductRemodulin526,800,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductTyvaso DPI1,292,500,000USD0001082554-26-000006
    FY 2025Yearly · 2025-12-31ProductUnituxin226,800,000USD0001082554-26-000006
    Q3 2025Quarterly · 2025-09-30GeographyInternational24,700,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30GeographyUnited States774,800,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductAdcirca9,700,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductNebulized Tyvaso141,800,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductOrenitram131,100,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductProduct And Service Other6,900,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductRemodulin125,900,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductTyvaso DPI336,200,000USD0001082554-25-000034
    Q3 2025Quarterly · 2025-09-30ProductUnituxin47,900,000USD0001082554-25-000034
    Q2 2025Quarterly · 2025-06-30GeographyInternational38,800,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30GeographyUnited States759,800,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductAdcirca6,500,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductNebulized Tyvaso154,400,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductOrenitram123,900,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductProduct And Service Other5,500,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductRemodulin134,700,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductTyvaso DPI315,200,000USD0001628280-25-036541
    Q2 2025Quarterly · 2025-06-30ProductUnituxin58,400,000USD0001628280-25-036541
    Q1 2025Quarterly · 2025-03-31GeographyInternational44,800,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31GeographyUnited States749,600,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductAdcirca6,000,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductNebulized Tyvaso163,800,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductOrenitram120,700,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductProduct And Service Other5,000,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductRemodulin138,200,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductTyvaso DPI302,500,000USD0001082554-26-000020
    Q1 2025Quarterly · 2025-03-31ProductUnituxin58,200,000USD0001082554-26-000020
    Q4 2024Quarterly · 2024-12-31GeographyInternational30,200,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States705,700,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductAdcirca4,700,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductNebulized Tyvaso142,700,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOrenitram107,800,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductProduct And Service Other5,500,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductRemodulin134,500,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductTyvaso DPI273,200,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductUnituxin67,500,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational137,700,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31GeographyUnited States2,739,700,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductAdcirca23,800,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductNebulized Tyvaso586,800,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductOrenitram434,300,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductProduct And Service Other22,100,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductRemodulin538,100,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductTyvaso DPI1,033,600,000USD0001082554-26-000006
    FY 2024Yearly · 2024-12-31ProductUnituxin238,700,000USD0001082554-26-000006
    Q3 2024Quarterly · 2024-09-30GeographyInternational31,600,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30GeographyUnited States717,300,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductAdcirca7,000,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductNebulized Tyvaso159,200,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductOrenitram113,200,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductProduct And Service Other5,500,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductRemodulin128,300,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductTyvaso DPI274,600,000USD0001082554-25-000034
    Q3 2024Quarterly · 2024-09-30ProductUnituxin61,100,000USD0001082554-25-000034
    FY 2023Yearly · 2023-12-31GeographyInternational125,300,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31GeographyUnited States2,202,200,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductAdcirca28,900,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductNebulized Tyvaso502,600,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductOrenitram359,400,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductProduct And Service Other11,800,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductRemodulin494,800,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductTyvaso DPI731,100,000USD0001082554-26-000006
    FY 2023Yearly · 2023-12-31ProductUnituxin198,900,000USD0001082554-26-000006
    FY 2022Yearly · 2022-12-31GeographyInternational122,200,000USD0001082554-25-000005

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.